NCT03135171已完成1 期
A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 3
- 主要终点
- Recommended Phase II Dose of Tocilizumab
研究概览
简要总结
The goal in this Phase 1 dose-escalation trial of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2 positive breast cancer is to determine the safety, tolerability and recommended Phase 2 dose of tocilizumab given with trastuzumab and pertuzumab every 3 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women or men with histologically confirmed breast cancer that overexpresses HER2 (defined by ASCO-CAP 2013 guidelines performed using FDA-approved tests by laboratories with demonstrated proficiency) that is metastatic or unresectable
- •Subjects must have received trastuzumab in the metastatic setting and experienced disease progression on this drug.
- •Any number of prior therapies is permitted. Prior therapy with other HER2 targeted agents (TDM-1, pertuzumab, lapatinib) is allowed.
- •The last dose of chemotherapy must have occurred ≥3 weeks prior to study registration.
- •The last radiation therapy must have occurred ≥3 weeks prior to study registration.
- •Age≥ 18 years
- •Eastern Cooperative Oncology Group Performance Status of 0 or 1 (An attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)
- •Measurable and/or non-measureable disease by RECIST criteria must be present.
- •Adequate organ and bone marrow function
- •Subjects with treated brain metastases are eligible provided the metastases are clinically stable and greater than 8 weeks has elapsed from time of treatment and date of initiation of study drug.
- •Males and females of reproductive potential must use two forms of effective contraception during the duration of the trial and for minimum of 7 months after last dose of tocilizumab, trastuzumab, or pertuzumab.
排除标准
- •Intolerance to previous trastuzumab or pertuzumab therapy
- •Previous treatment with tocilizumab or other cytokine-targeted biologic disease modifying antirheumatic drugs (including adalimumab, certolizumab, etanercept, golimumab, infliximab, anakinra) within 3 months of enrollment
- •Participation in other investigational studies concurrently if these therapies include a therapeutic intervention
- •Treatment with any investigational agent within 30 days (or 5 serum half-lives of the investigational drug, whichever is longer) of enrollment
- •Concurrent second malignancy or history of HER2 negative breast cancer within five years
- •Comorbidity or intercurrent illness
- •Major surgery within 8 weeks or planned major surgery during study and up to 6 months after discontinuation of study drug
- •Left ventricular systolic dysfunction, defined as ejection fraction below institutional normal by echocardiography or MUGA (multigated acquisition scan); current or past clinical diagnosis of congestive heart failure; history of ejection fraction decreased to below institutional normal or desease of greater than 15% attributable to past trastuzumab or pertuzumab therapy
- •Evidence of current serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease.
- •History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower GI (gastrointestinal) disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations
- •Infections as detailed in the protocol
- •Immunization with a live/attenuated vaccine within 30 days of enrollment
- •Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
- •Pre-existing CNS (Central Nervous System) demyelination or seizure disorders
- •Any medical or psychological condition that in the opinion of the principal investigator would interfere with safe completion of the trial
- •Pregnancy or breastfeeding
研究组 & 干预措施
Trastuzumab, Pertuzumab and Tocilizumab
Experimental
干预措施: Trastuzumab (Drug)
Trastuzumab, Pertuzumab and Tocilizumab
Experimental
干预措施: Pertuzumab (Drug)
Trastuzumab, Pertuzumab and Tocilizumab
Experimental
干预措施: Tocilizumab (Drug)
结局指标
主要结局
Recommended Phase II Dose of Tocilizumab
时间窗: 10 weeks
The primary objective is to determine the highest dose level of tocilizumab (up to 8 mg/kg every 3 weeks) that, when given in combination with trastuzumab and pertuzumab every three weeks in subjects with HER2 positive metastatic breast cancer, will result in less than 25% incidence of DLT. DLTs (Dose Limiting Toxicity) will be assessed within the first two cycles (up to 10 weeks) and defined as any toxicity of grade 3 or 4, unless specifically described in the protocol.
次要结局
- The Frequency of Adverse Events at Each Dose Level(30 days after last treatment dose)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)Acute Myeloid Leukemia (AML)NCT04547062Nantes University Hospital12
已完成
2 期
Randomized, open-label, multicenter trial to assess humanized anti-IL-6 receptor antibody, tocilizumab, for the treatment of systemic sclerosisSystemic sclerosisJPRN-UMIN000005550Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine24
招募中
1 期
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMAcute Myeloid Leukemia (AML)NCT05697510Nantes University Hospital12
终止
2 期
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 InfectionCOVID-19NCT04377659Memorial Sloan Kettering Cancer Center9
已完成
2 期
ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI TrialCoronary DiseaseMyocardial InfarctionNCT03004703Oslo University Hospital200